Skip to main content

A Primer for Family Medicine and Primary Care: Focusing on Pompe Disease

Tracking # 20-686715

Free

There are no ratings for this course

Learn more
CE Broker Reporting Reported automatically
Method Computer-Based Training

Course overview

Recognizing Pompe disease, a progressive, debilitating and often fatal neuromuscular disease caused by a genetic deficiency or dysfunction of the lysosomal enzyme acid alpha-glucosidase (GAA), can be challenging, as its signs and symptoms are like those of other diseases and disorders. As a result, Pompe disease may not be readily considered during the clinical work up and significant diagnostic delays are common in many patients. During this activity, we shall review the importance of early diagnosis, how the disease can present at different ages through sample case vignettes, as well as discuss advances in the ongoing monitoring and management of these patients. Early recognition is critical for improved outcomes since the disease continues to progress relentlessly, with many patients going undiagnosed for years, with debilitating and often life-threatening impact.

Subject areas

This course counts toward the state boards and subject areas below.

Bahamas Medical Council

Medical Practitioner

1h Family Medicine
1h General Medicine
1h Internal Medicine
1h Pediatrics
1h Continuing Medical Education

Specialty Medical Practitioner

1h Pediatrics
1h Continuing Medical Education
1h General Medicine
1h Pediatric Surgery
1h Internal Medicine

New Mexico Board of Nursing

Registered Nurse

1h Continuing education relevant to nursing practice

State Medical Board of Ohio

Doctor of Medicine

1h AMA Category I

Doctor of Osteopathic Medicine

1h AMA Category I

West Virginia Board of Registered Nurses

Advanced Practice Registered Nurse

1h Professional nursing practice and special health care problems

Registered Nurse

1h Professional nursing practice and special health care problems

Disclosure statements

Presenter: Priya Kishnani, MD has indicated that she has received research grant support from Sanofi Genzyme, Valerion Therapeutics, and Amicus Therapeutics; consulting fees and honoraria from Sanofi Genzyme, Amicus Therapeutics, Vertex, and Asklepios Biopharmaceutical (AskBio), and is a member of the Pompe and Gaucher disease advisory board for Sanofi Genzyme, Amicus Therapeutics, and Baebies. She also has equity in AskBio Therapeutics.

Peer reviewer and EXCEL staff have no relevant financial information to disclose.